Detailed Information on Publication Record
2017
Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies
KRALICKOVA, P., J. KUHNOVA, O. SOUCEK, P. VODAREK, P. ZAK et. al.Basic information
Original name
Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies
Authors
KRALICKOVA, P. (203 Czech Republic), J. KUHNOVA (203 Czech Republic), O. SOUCEK (203 Czech Republic), P. VODAREK (203 Czech Republic), P. ZAK (203 Czech Republic), M. SIMKOVIC (203 Czech Republic), M. MOTYCKOVA (203 Czech Republic), L. SMOLEJ (203 Czech Republic), E. MALA (203 Czech Republic), C. ANDRYS (203 Czech Republic), J. KREJSEK (203 Czech Republic) and Vojtěch THON (203 Czech Republic, guarantor, belonging to the institution)
Edition
Journal of Immunology Research, London, Hindawi, 2017, 2314-8861
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30102 Immunology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.298
RIV identification code
RIV/00216224:14110/17:00099077
Organization unit
Faculty of Medicine
UT WoS
000419035800001
Keywords in English
Pneumococcal Capsular Polysaccharides; Natural Anti-Galactosyl; Humoral Immunodeficiencies
Tags
Tags
International impact, Reviewed
Změněno: 21/3/2018 16:27, Soňa Böhmová
Abstract
V originále
Humoral deficiencies represent a broad group of disorders. The aim of the study was to compare the levels of antibodies against pneumococcal capsular polysaccharides (anti-PCP) and natural anti-galactosyl (anti-Gal) antibodies in (1) patients with chronic lymphocytic leukaemia (CLL), (2) patients with common variable immunodeficiency (CVID), and (3) a healthy population and to explore their diagnostic and prognostic potential. Serum immunoglobulin levels and levels of anti-Gal IgG, IgA, and IgM and anti-PCP IgG and IgG2 were determined in 59 CLL patients, 30 CVID patients, and 67 healthy controls. Levels of IgG, IgA, IgM, anti-Gal IgA, anti-Gal IgM, and anti-PCP IgA were lower in CLL and CVID patients than in healthy controls. Decrease in the levels of IgA, IgM, anti-Gal IgA, and anti-PCP IgA was less pronounced in the CLL group than in the CVID group. IgA decline, anti-Gal IgA, anti-PCP IgA, and anti-PCP IgG2 were negatively correlated with CLL stage. We devise the evaluation of anti-Gal antibodies to be a routine test in humoral immunodeficiency diagnostics, even in cases of immunoglobulin substitution therapy. Significant reductions, mainly in anti-Gal IgA, IgM, and anti-PCP IgA levels, may have prognostic importance in CLL patients.